Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerated Biological Aging Increases the Risk of Head and Neck Cancer: Insights From Genetic Instruments of Epigenetic Clocks.

Molecular carcinogenesis·2026
Same author

Genetic Insights into Interleukin-13 Polymorphisms in Colorectal Cancer Risk and Progression.

Cancer genomics & proteomics·2026
Same author

Insights into Matrix Metalloproteinase-2 Genotypes, Smoking, Alcohol Drinking, Hypertension and Renal Cell Carcinoma in Taiwan.

Anticancer research·2026
Same author

8-Gingerol Mitigates MPP<sup>+</sup>-Induced α-Synuclein Aggregation and NLRP3 Inflammasome Activation by Inducing the Insulin Signaling Pathway in SH-SY5Y Cells.

Neurochemical research·2026
Same author

MMP-9 Genotypes Serve as Oral Cancer Predictive Marker for Smokers.

Anticancer research·2026
Same author

<i>Artemisia indica</i> Willd. Extract Regulate NLRP3 Inflammasome and ENaC Trafficking in Angiotensin II-Stimulated Renal Tubular Cells.

Plants (Basel, Switzerland)·2026
Same journal

Time-Dependent Inflammatory Cytokine Responses in a Human Fetal Membrane Dual-Compartment Model.

In vivo (Athens, Greece)·2026
Same journal

Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study.

In vivo (Athens, Greece)·2026
Same journal

Nutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study.

In vivo (Athens, Greece)·2026
Same journal

Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management.

In vivo (Athens, Greece)·2026
Same journal

Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells <i>In Vitro</i>.

In vivo (Athens, Greece)·2026
Same journal

Prognostic Value of Liver Function-based Scores in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.

In vivo (Athens, Greece)·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Exploring the Contribution of Interleukin-12A Genetic Polymorphisms to Pterygium Risk.

Ya-Chen Yang1, Ning-Yi Hsia2, Te-Chun Hsia3,4,5

  • 1Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, R.O.C.

In Vivo (Athens, Greece)
|June 30, 2026
PubMed
Summary
This summary is machine-generated.

Genetic variations in IL-12A were not linked to pterygium susceptibility in this study. Further research is needed to understand the role of Interleukin-12 in pterygium development.

Keywords:
GenotypesTaiwaninterleukin-12pterygiumsingle nucleotide polymorphism

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jul 2, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Area of Science:

  • Ophthalmology
  • Immunogenetics
  • Molecular Biology

Background:

  • Pterygium is a common eye condition influenced by environmental factors and immune responses.
  • Interleukin-12 (IL-12) is a key cytokine in inflammation, but its genetic role in pterygium is unknown.

Purpose of the Study:

  • To investigate the association between IL-12A gene polymorphisms and susceptibility to pterygium.
  • To determine if specific IL-12A genetic variations contribute to pterygium development.

Main Methods:

  • A case-control study involving 160 pterygium patients and 320 controls.
  • Genotyping of IL-12A polymorphisms (rs568408 and rs2243115) using restriction fragment length polymorphism.

Main Results:

  • No significant differences in genotype or allele frequencies of IL-12A polymorphisms between pterygium cases and controls.
  • Neither rs568408 nor rs2243115 polymorphisms showed a significant association with pterygium risk.

Conclusions:

  • IL-12A gene polymorphisms are not significantly associated with pterygium susceptibility.
  • IL-12-mediated immune pathways might influence pterygium pathogenesis through functional mechanisms, not just genetic variations.
  • Further large-scale and mechanistic studies are recommended to explore IL-12's role.